On Thursday, Smith & Nephew ADR earned a positive adjustment to its Relative Strength (RS) Rating, from 67 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves. See if Smith & Nephew ADR can continue to rebound and hit that benchmark.
Smith & Nephew ADR is working on a consolidation with a 31.72 entry. See if it can clear the breakout price in volume at least 40% higher than normal.
The company reported -2% EPS growth last quarter. Revenue gains came in at 6%. The company is expected to report its latest earnings and sales numbers on or around Apr. 30.
The company earns the No. 25 rank among its peers in the Medical-Products industry group. Pro-Dex, Boston Scientific and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
